PMID: 7525850Dec 1, 1994Paper

Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production

The Journal of Experimental Medicine
N KarinL Steinman

Abstract

An immunodominant epitope of myelin basic protein (MBP), VHFFKNIVTPRTP (p87-99), is a major target of T cells in lesions of multiple sclerosis (MS) and in experimental allergic encephalomyelitis (EAE). T cells found in EAE lesions bear the same amino acids in the third complementary determining region of the T cell receptor (TCR) as those found in MS lesions. We analyzed the trimolecular interactions between MBP p87-99, class II major histocompatibility complex (MHC), and TCR, and designed soluble inhibitors for therapy. F, N, I, and V at positions 90, 92, 93, and 94 interact with MHC, whereas K, T, and P at positions 91, 95, and 96 interact with TCR. The peptides, p87-99[95T > A] and p87-99[96P > A] could compete more effectively with p87-99 for binding to MHC and could antagonize the in vitro response to T cells to p87-99 more effectively than p87-99[91K > A]. However, only p87-99[91K > A] prevented and reversed EAE, indicating that the extent of MHC or TCR competition does not predict success in treating EAE. To elucidate the mechanism of inhibition of EAE, draining lymph node cells from rats immunized with the native peptide alone or together with each of the three TCR antagonists were challenged in vitro with p87-99. Admin...Continue Reading

References

Oct 1, 1991·The Journal of Experimental Medicine·A MillerH L Weiner
Nov 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·D E SmilekH O McDevitt
Dec 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·S D SharmaS Sriram
Nov 1, 1991·Annals of Neurology·K SelmajA H Cross
Aug 15, 1991·The New England Journal of Medicine·M K Sharief, R Hentges
Nov 1, 1991·Journal of Neuroimmunology·Y Kuroda, Y Shimamoto
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·K SakaiL Steinman
Dec 1, 1988·Immunological Reviews·C V HardingE R Unanue
Jul 1, 1973·Archives of Neurology·B CampbellR Lorenz
Oct 1, 1983·The Journal of Experimental Medicine·S Sriram, L Steinman
Nov 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·L SteinmanH O McDevitt
Jan 18, 1994·Proceedings of the National Academy of Sciences of the United States of America·A M GautamH O McDevitt
Apr 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·J RuppertA Sette

❮ Previous
Next ❯

Citations

Mar 27, 2001·European Journal of Immunology·M P RileyA J Caton
Jan 1, 1996·Springer Seminars in Immunopathology·R Martin, H McFarland
Apr 29, 1998·Biotherapy·J M van Noort
Nov 12, 2009·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Joseph J SabatinoBrian D Evavold
Mar 20, 2002·Current Neurology and Neuroscience Reports·B Gran, A Rostami
Mar 3, 2011·Immunologic Research·Lindsay J Edwards, Brian D Evavold
Oct 9, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Lawrence Steinman
Jul 22, 1998·Journal of Neuroimmunology·R B SmeltzR H Swanborg
May 20, 1998·Research in Immunology·M G von Herrath
Mar 11, 1998·Current Opinion in Immunology·A O'GarraK Gijbels
Apr 7, 2005·Nature Medicine·Mark Larché, David C Wraith
Aug 11, 2007·Nature Reviews. Immunology·Stephen D MillerJoseph R Podojil
Apr 29, 1998·Immunology and Cell Biology·D O Willenborg, M A Staykova
Nov 27, 1997·The New England Journal of Medicine·R A RudickR M Ransohoff
Apr 1, 1996·The Journal of Experimental Medicine·K VidalP M Allen
Apr 20, 1999·The Journal of Experimental Medicine·P J RuizL Steinman
Oct 23, 2002·The Journal of Experimental Medicine·Lukas HunzikerRolf M Zinkernagel
Jul 1, 1997·Inflammatory Bowel Diseases·B E Sands
May 25, 2007·The Journal of Pharmacology and Experimental Therapeutics·Naoki KobayashiTeruna J Siahaan
Dec 1, 1999·Annals of the Rheumatic Diseases·C LockL Steinman
Sep 5, 2002·The Journal of Clinical Investigation·Gizi WildbaumNathan Karin
Nov 11, 2009·Arthritis Research & Therapy·Keiichi IwanamiTakayuki Sumida
Mar 25, 1998·Journal of the Neurological Sciences·D M Karussis, O Abramsky
Aug 5, 2004·Proceedings of the National Academy of Sciences of the United States of America·Joel N H SternJack L Strominger
Jan 25, 2005·Proceedings of the National Academy of Sciences of the United States of America·Joel N H SternJack L Strominger
Aug 19, 1997·Proceedings of the National Academy of Sciences of the United States of America·L B NicholsonV K Kuchroo
Jun 18, 2014·Journal of Neurotrauma·Amy L Bowes, Ping K Yip

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.